Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)

Status Active, not recruiting

Clinical Trial Summary

Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown. Here, we enrolled treatment naive CHB patients with biopsy-proven significant fibrosis (METAVIR fibrosis stage ≥ F2). All enrolled subjects will be treated with TAF monotherapy for 96 weeks. After 96 weeks of therapy, the second liver biopsy will be performed to evaluate the rate of liver fibrosis regression. During this study, all subjects will be assessed for laboratory tests, imaging examination at baseline, first 12-week and every 24-week during follow-up.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04939441
Study type	Interventional
Source	Beijing Friendship Hospital
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	April 20, 2021
Completion date	May 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04496882` - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue	Phase 4
Completed	`NCT04083716` - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults	Phase 1
Not yet recruiting	`NCT03038802` - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection	Phase 1/Phase 2
Completed	`NCT05310487` - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects	Phase 1
Recruiting	`NCT06070051` - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy	Phase 1
Terminated	`NCT05001022` - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects	Phase 1
Recruiting	`NCT04139850` - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting	`NCT05343481` - Efficacy of VTP-300 in Chronic Hepatitis B Infection	Phase 2
Not yet recruiting	`NCT05490836` - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients	N/A
Recruiting	`NCT04543565` - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study	Phase 3
Active, not recruiting	`NCT02894918` - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs	Phase 4
Not yet recruiting	`NCT02793791` - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients	N/A
Recruiting	`NCT02287857` - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B	N/A
Recruiting	`NCT01965418` - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial	Phase 4
Recruiting	`NCT01491295` - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients	Phase 4
Terminated	`NCT01872988` - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma	Phase 3
Recruiting	`NCT01487876` - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients	Phase 2
Not yet recruiting	`NCT01436539` - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients	Phase 4
Completed	`NCT01531166` - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon	N/A
Recruiting	`NCT01360892` - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography	N/A